Fund Portfolio

IntraLase Corporation - IPO 10/7/04
Date of initial investment: May 1998
Principal co-investors: EDF Ventures, Brentwood Venture Capital
Co-founded with scientists from the University of Michigan's Kellogg Eye Center, California-based IntraLase is advancing the next generation of ophthalmic lasers to correct myopic vision problems.

HandyLab
Investments: June 2000, September 2000, November 2001, May 2002, May 2004, December 2005
Principal co-investor: EDF Ventures, Arboretum Ventures, Ardesta, Pfizer Ventures
Started by two recently minted University of Michigan Ph.D.'s in Chemical Engineering, Ann Arbor-based HandyLab has developed methods for miniaturizing medical tests so that they can be instantly conducted on a handheld computer in a doctor's office.

Silverpop Systems
Investment: August 2000
Principal co-investor: Draper Fisher Jurvetson 
Atlanta-based Silverpop Systems has developed a distributed computer network that allows for the distribution of "rich" content over the Internet, e.g., e-mails that contain audio and video in a significantly improved fashion.

Mobius Microsystems, Inc.
Investment: April 2004
Principal co-investors: Waypoint Ventures, Angel Funds
California-based Mobius empowers integrated circuit designers and manufacturers to achieve previously unattainable levels of analog and mixed-signal integration across all process technologies.

Direct Flow Medical, Inc.
Investment: March 2005
Principal co-investors: EDF Ventures
Headquartered in Santa Rosa, California, Direct Flow Medical is a medical device company that is developing a stentless system for the percutaneous replacement of the aortic valve.

Nanocerox
Investment: November 2005
Principal co-investors: Angel Funds
Founded in 1996 on technology developed at the University of Michigan, Nanocerox produces mixed metal oxide nanoscale ceramic powders. These materials have a wide variety of applications, including military armor, paint pigments, lighting components and sensors.

NanoBio
Investment: March 2006
Principal co-investors: Angel Funds
Headquartered in Ann Arbor, Nanobio focuses on developing and commercializing dermatological products, topical anti-infectives, and vaccines.

Rhevision Technology
Investment: March 2006
Principal co-investors: EDF Ventures, In-Q-Tel Ventures
California-based Rhevision Technology develops miniature tunable camera lenses. The first products being developed are optical auto-focus and zoom lens assemblies targeting the high-growth camera phone market.

 
IntelePeer Inc.
Investment: January 2008
Principal co-investors: Kennet Venture Partners, IVS Fund, EDF Ventures
IntelePeer is a VoIP managed-service provider offering global peering infrastructure, network interoperability, industry-leading quality of service, and advanced VoIP-enabled applications.

Accord Biomaterials Inc
Investment: April 2008
Principal co-investors: Arboretum Ventures, Sigvion Capital
Accord Biomaterials is a Michigan-based company that focuses on the development of catalytic nitric oxide coatings for blood-contacting medical devices. These coatings address serious complications related to clotting and altered healing. The technology is licensed from the University of Michigan.

Quantum Learning Technologies
Investment: April 2008
Principal co-investors: RPM Ventures
Quantum Learning Technologies is a Michigan-based online educational community that enables children to reach their academic potential by embedding scientifically-based educational activities in engaging, interactive programs that incorporate computer game design techniques.

Environmental Operating Solutions Inc.
Investment: July 2008
Principal co-investors: Stuart Mill Venture Partners
Based in Massachusetts, Environmental Operating Solutions provides solutions for the removal of nitrate-nitrogen in the wastewater treatment process. The company delivers safer and more economical and environmentally sustainable denitrification solutions.

Lycera Corporation
Investment: July 2008
Principal co-investors: EDF Ventures, Angel Investors
Based in Michigan, Lycera is developing therapeutics for diseases of the immune system: such as tissue rejection in transplants, rheumatoid arthritis and lupus.